

# Contents

|  |             |
|--|-------------|
| <b>Acknowledgements</b> .....  | <b>I</b>    |
| <b>Abstract</b> .....  | <b>III</b>  |
| <b>Zusammenfassung</b> .....   | <b>V</b>    |
| <b>Abbreviations</b> .....   | <b>XI</b>   |
| <b>Amino acids</b> .....   | <b>XIII</b> |
| <b>1 Introduction</b> .....  | <b>1</b>    |
| 1.1 Netherton syndrome .....   | 1           |
| 1.1.1 Disease .....  | 1           |
| 1.1.2 Molecular background .....   | 2           |
| 1.1.3 Tissue kallikreins.....  | 5           |
| 1.1.4 LEKTI .....  | 10          |
| 1.1.5 KLK5 and KLK7 inhibitors .....                                     | 11          |
| 1.1.6 Mouse models .....   | 13          |
| 1.2 Peptides in drug development .....                                   | 15          |
| 1.2.1 Peptides as drug modality.....                                     | 15          |
| 1.2.2 Directed evolution in drug development .....                       | 18          |
| 1.2.3 <i>In vitro</i> selection of peptides.....                         | 21          |
| 1.2.4 Phage display of bicyclic peptides .....                           | 24          |
| 1.2.5 Improvement of pharmacological properties .....                    | 27          |
| <b>2 Aim of this work</b> .....  | <b>33</b>   |
| <b>3 Results &amp; Discussion</b> .....                                  | <b>35</b>   |
| 3.1 Phage selection of bicyclic peptide inhibitors of KLK5 and KLK7..... | 35          |
| 3.1.1 Choice of target proteins.....                                     | 35          |
| 3.1.2 Expression strategies and constructs .....                         | 36          |
| 3.1.3 Expression, purification and characterization.....                 | 37          |

|          |   |           |
|----------|---|-----------|
| 3.1.4    | Biotinylation of KLKs for immobilization .....                    | 40        |
| 3.1.5    | Selection & characterization of bicyclic peptides .....           | 41        |
| 3.2      | Structure activity relationship and affinity improvement .....    | 47        |
| 3.2.1    | Development of monocyclic peptide inhibitors .....                | 47        |
| 3.2.2    | Affinity improvement with unnatural amino acids .....             | 49        |
| 3.2.3    | Selectivity .....   | 52        |
| 3.3      | Half-life extension and pharmacokinetics .....                    | 53        |
| 3.3.1    | Conjugation to albumin tag .....                                  | 53        |
| 3.3.2    | Plasma stability of inhibitors .....                              | 58        |
| 3.3.3    | Stability improvement of KLK7 inhibitor .....                     | 58        |
| 3.3.4    | Replacement of fluorescein in albumin tag .....                   | 60        |
| 3.3.5    | Final inhibitors .....  | 64        |
| 3.3.6    | Pharmacokinetics in mice .....                                    | 65        |
| 3.4      | Skin distribution .....   | 68        |
| 3.4.1    | Biodistribution to skin and organs .....                          | 68        |
| 3.4.2    | Skin distribution of peptide versus antibody .....                | 70        |
| 3.5      | Peptides for efficacy studies .....                               | 76        |
| 3.5.1    | Inhibition of mouse KLKs .....                                    | 76        |
| 3.5.2    | Negative control inhibitors .....                                 | 76        |
| 3.5.3    | Batch synthesis .....   | 77        |
| 3.5.4    | Formulation .....   | 79        |
| 3.5.5    | Efficacy studies .....  | 81        |
| <b>4</b> | <b>Conclusion &amp; Outlook .....</b>                             | <b>83</b> |
| 4.1      | Are the inhibitors better than the state-of-the-art? .....        | 83        |
| 4.1.1    | Comparison of our inhibitors with LEKTI .....                     | 83        |
| 4.1.2    | Comparison of our KLK7 inhibitor to the cyclic depsipeptide ..... | 85        |
| 4.1.3    | Comparison to engineered sunflower trypsin inhibitors .....       | 86        |
| 4.2      | Are the inhibitors good enough for therapy? .....                 | 88        |
| 4.2.1    | Affinity .....  | 88        |
| 4.2.2    | Specificity and toxicity .....                                    | 89        |
| 4.2.3    | Stability and pharmacokinetics .....                              | 89        |
| 4.2.4    | Biodistribution .....   | 90        |
| 4.2.5    | Efficacy .....  | 90        |
| 4.3      | Outlook .....   | 92        |

|          |   |           |
|----------|---|-----------|
| 4.3.1    | Inhibitors for the systemic treatment of Netherton syndrome ..... | 92        |
| 4.3.2    | Inhibitors for topical administration .....                       | 94        |
| <b>5</b> | <b>Materials &amp; Methods .....</b>                              | <b>95</b> |
| 5.1      | Materials .....   | 95        |
| 5.1.1    | Peptide synthesis reagents .....                                  | 95        |
| 5.1.2    | Peptide synthesis building blocks .....                           | 96        |
| 5.1.3    | Biochemical reagents .....  | 97        |
| 5.1.4    | Proteins & substrates .....                                       | 98        |
| 5.1.5    | Kits & consumables .....  | 99        |
| 5.2      | Protein expression .....  | 100       |
| 5.2.1    | Expression and purification of KLK5 and KLK7 .....                | 100       |
| 5.2.2    | Biotinylation of targets .....                                    | 101       |
| 5.3      | Phage display selections .....                                    | 102       |
| 5.3.1    | Phage display library .....                                       | 102       |
| 5.3.2    | Phage production and modification .....                           | 102       |
| 5.3.3    | Biopanning .....  | 103       |
| 5.3.4    | Phage sequencing .....  | 104       |
| 5.4      | Peptide synthesis .....   | 105       |
| 5.4.1    | Automated peptide synthesis .....                                 | 105       |
| 5.4.2    | Fluorescein and fatty acid conjugation on solid phase .....       | 105       |
| 5.4.3    | Peptide cleavage and deprotection .....                           | 105       |
| 5.4.4    | Palmitic acid and silicon rhodamine coupling in solution .....    | 106       |
| 5.4.5    | Cyclization with thiol-reactive linkers .....                     | 106       |
| 5.4.6    | Synthesis of para-nitroanilide substrates .....                   | 106       |
| 5.4.7    | Peptide purification .....  | 107       |
| 5.5      | Labeling of biomolecules .....                                    | 108       |
| 5.6      | <i>In vitro</i> characterization .....                            | 109       |
| 5.6.1    | Analysis of peptide mass and purity .....                         | 109       |
| 5.6.2    | Protease inhibition assays .....                                  | 109       |
| 5.6.3    | Fluorescence polarization albumin binding assay .....             | 111       |
| 5.6.4    | Plasma stability assay .....                                      | 111       |
| 5.7      | Pharmacokinetic studies in mice .....                             | 113       |
| 5.7.1    | Peptide concentrations in blood .....                             | 113       |
| 5.7.2    | Fluorescence imaging of organs .....                              | 113       |

|          |  |            |
|----------|--|------------|
| 5.7.3    | Preparation and fluorescence microscopy of skin sections ..... | 114        |
| <b>6</b> | <b>Supporting information .....</b>                            | <b>115</b> |
| 6.1      | Phylogeny of KLKs .....  | 116        |
| 6.2      | Structure of human serum albumin.....                          | 117        |
| 6.3      | Synthesis schemes .....  | 118        |
| 6.4      | Raw data .....   | 120        |
| 6.4.1    | Affinity improvement .....                                     | 120        |
| 6.4.2    | Stability of inhibitors.....                                   | 121        |
| 6.4.3    | Stability improvement of KLK7 inhibitor .....                  | 122        |
| 6.4.4    | Stability in mouse plasma .....                                | 123        |
| 6.4.5    | Degradation fragments in mice .....                            | 123        |
| 6.4.6    | Biodistribution .....  | 124        |
| 6.5      | Overview of binding constants .....                            | 125        |
| 6.6      | Peptide purities & masses.....                                 | 126        |
|          | <b>References .....</b>  | <b>157</b> |